MedTrace Logo

(Val)Ganciclovir TDM in Transplant Recipients

NCT03698435 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2019-10-10

No results posted yet for this study

Summary

The aim of this study is to gain more insight into therapeutic drug monitoring and thus the pharmacodynamics and pharmacokinetics of ganciclovir, in the context of prophylaxis and treatment of CMV infections, in order to provide the patient with an adequate dose.

Conditions

  • Cytomegalovirus Infections

Interventions

DRUG

Ganciclovir

Intravenous ganciclovir + TDM

DRUG

Valganciclovir

Oral valganciclovir + TDM

Sponsors & Collaborators

  • University Medical Center Groningen

    lead OTHER

Principal Investigators

  • Jan-Willem Alffenaar, PhD · University Medical Center Groningen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-25
Primary Completion
2019-11-30
Completion
2019-12-31
FDA Drug
Yes

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03698435 on ClinicalTrials.gov